JP Morgan Maintains Overweight on Braze, Lowers Price Target to $34
JP Morgan analyst Alexei Gogolev maintains Braze (NASDAQ:BRZE) with a Overweight and lowers the price target from $35 to $34.
Stocks · News reference
Full Transcript: Braze Q2 2027 Earnings Call
On Wednesday, Braze (NASDAQ:BRZE) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Buy on Braze, Raises Price Target to $37
Canaccord Genuity analyst David Hynes maintains Braze (NASDAQ:BRZE) with a Buy and raises the price target from $35 to $37.
Raymond James Maintains Outperform on Braze, Raises Price Target to $33
Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $27 to $33.
UBS Maintains Buy on Braze, Raises Price Target to $32